Approved Research

Interrogation of Olink serum Proteomics across cancer, healthy, and other disease contexts

Lay summary

The team at Parthenon Therapeutics is developing novel therapeutics to address mechanisms of cancer resistance to immunotherapy. With access to the UK biobank data, we are interested in understanding the relationship between a list of potential serum protein markers and relevance to cancer. This analysis will support biomarker design for clinical trials of novel therapies for treatment of cancer with the hope that these treatments will provide benefit to patients have otherwise have not benefited from other standard-of-care treatments.